ALTEOGEN Inc. (KOSDAQ:196170)
South Korea · Delayed Price · Currency is KRW 369,000
+11,500 (3.22%)
Apr 24, 2026, 3:30 PM KST
ALTEOGEN Revenue
In the year 2025, ALTEOGEN had annual revenue of 215.86B KRW with 109.87% growth. ALTEOGEN had revenue of 64.51B in the quarter ending December 31, 2025, with 26.91% growth.
Revenue
215.86B
Revenue Growth
+109.87%
P/S Ratio
91.47
Revenue / Employee
1.36B
Employees
159
Market Cap
19.75T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 215.86B | 113.00B | 109.87% |
| Dec 31, 2024 | 102.85B | 6.33B | 6.56% |
| Dec 31, 2023 | 96.52B | 67.72B | 235.08% |
| Dec 31, 2022 | 28.81B | -9.94B | -25.65% |
| Dec 31, 2021 | 38.75B | -3.68B | -8.67% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4.56T |
| Celltrion | 4.16T |
| Samsung Epis Holdings | 1.51T |
| SK Biopharmaceuticals | 706.74B |
| SK bioscience | 651.37B |
| LigaChem Biosciences | 141.55B |
| HLB Co., Ltd. | 84.17B |
| OliX Pharmaceuticals | 14.67B |
ALTEOGEN News
- 4 weeks ago - Alteogen Stock Up On Upto $579 Mln Deal With Biogen For Hybrozyme-Based Subcutaneous Biologics - Nasdaq
- 7 months ago - FDA Clears Merck's One-Minute Cancer Shot - Benzinga